Cardium Therapeutics Inc. reported consolidated financial results for the second quarter and six months ended June 30, 2013. Product sales for the three months ended June 30, 2013 totaled $585,000, compared to $13,000 for the same period in 2012. Loss from operations was $2,117,020 against $1,876,870 a year ago. Net loss applicable to common stockholders was $2,350,559 or $0.37 basic and diluted per share against $1,875,447 or $0.31 basic and diluted per share a year ago.

Product sales for the six months ended June 30, 2013 were $1.2 million, compared to $34,000 for the six months ended June 30, 2012. The increase in product sales was comprised of sales from the company's To Go Brands health sciences business, which Cardium acquired in late September 2012. Net loss was $4.4 million, or $0.72 per share, compared to a net loss for the six months ended June 30, 2012 of $4.5 million, or $0.78 per share. Loss from operations was $4,378,682 against $4,536,207 a year ago. Net loss applicable to common stockholders was $4,612,914 or $0.72 basic and diluted per share against $4,469,483 or $0.78 basic and diluted per share a year ago.